SELLAS (SLS)
Biotech
Close on Nov 17, 2026 (from our latest article): $19.15
- Market value
- $3.9Bat the Nov 17 close
- Cash used, 12 months
- $27M12 months to Sep 30, 2026 (10-Q)
- Net cash
- $135Mat Sep 30, 2026
- Worst fall since listing
- −100.0%Mar 13, 2008 to Jan 18, 2024; not back to that high (−100.0% now)
About the company
Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)
The Long View
What the filings say about the story, dilution and cash runway.
No Long View yet. Request one →
Our View Opinion
Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.
No Our View yet. Request one →
Long-term fundamentals
Annual results for SELLAS, FY2010–FY2025, as reported in its 10-K filings.
Revenue and free cash flow
Revenue went from $2M in FY2013 to $1M in FY2022.
Free cash flow was positive in 0 of the 6 years shown; FY2016: −$12M.
Margins
Margins are not charted: in FY2022 the operating loss (−$42M) was larger than revenue ($1M). The table has each year's figures.
Diluted share count
The diluted share count rose 1267% from FY2020 to FY2025, to 109M.
Results and cash flow
| Fiscal year | Revenue | Gross margin | Operating margin | Net income | Operating cash flow | Capital spending | Free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | — | — | −$27M | −$28M | — | — |
| FY2024 | — | — | — | −$31M | −$35M | — | — |
| FY2023 | $0 | — | — | −$37M | −$31M | — | — |
| FY2022 | $1M | — | −4195% | −$41M | −$24M | — | — |
| FY2021 | $8M | — | −333% | −$21M | −$26M | — | — |
| FY2020 | $2M | — | −894% | −$17M | −$10M | — | — |
| FY2019 | $0 | — | — | −$19M | −$18M | — | — |
| FY2018 | — | — | — | −$28M | −$30M | — | — |
| FY2017 | — | — | — | −$24M | −$11M | — | — |
| FY2016 | — | — | — | −$18M | −$12M | $0.0M | −$12M |
| FY2015 | — | — | — | −$64M | −$48M | $0.5M | −$49M |
| FY2014 | $9M | — | −471% | −$37M | −$43M | $3M | −$46M |
| FY2013 | $2M | — | −1146% | −$77M | −$29M | $16M | −$44M |
| FY2012 | $0 | — | — | −$35M | −$21M | — | — |
| FY2011 | $0 | — | — | −$11M | −$15M | $0.1M | −$15M |
| FY2010 | — | — | — | −$12M | −$10M | $0.1M | −$10M |
Shares, cash, debt and payouts
| Fiscal year | Diluted shares | Cash and investments | Debt | Stock-based pay | Dividends paid | Buybacks |
|---|---|---|---|---|---|---|
| FY2025 | 109M | $72M | — | $2M | — | — |
| FY2024 | 61M | $14M | — | $2M | — | — |
| FY2023 | 28M | $3M | — | $2M | — | — |
| FY2022 | 19M | $17M | — | $2M | — | — |
| FY2021 | 15M | $21M | — | $1M | — | — |
| FY2020 | 8.0M | $35M | — | $0.6M | — | — |
| FY2019 | — | $7M | — | $0.6M | $0 | — |
| FY2018 | — | $5M | $0 | $0.4M | $0.5M | — |
| FY2017 | — | $2M | $11M | $3M | $0 | — |
| FY2016 | — | $6M | $7M | $0.4M | — | — |
| FY2015 | — | $1M | $5M | $2M | — | — |
| FY2014 | — | $24M | $8M | $5M | — | — |
| FY2013 | — | $48M | $10M | $2M | — | — |
| FY2012 | — | $33M | $0 | $1M | — | — |
| FY2011 | — | $48M | — | $3M | — | — |
| FY2010 | — | $7M | — | $4M | — | $4M |
Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 17, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.
Returns by year
| Year | SLS | S&P 500 |
|---|---|---|
| 2019 | −93.0% | +31.5% |
| 2020 | +35.1% | +18.4% |
| 2021 | −4.8% | +28.7% |
| 2022 | −57.3% | −18.1% |
| 2023 | −55.1% | +26.3% |
| 2024 | −1.9% | +25.0% |
| 2025 | +262.5% | +17.9% |
| 2026 to date | +294.2% | +5.9% |
Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.
Other companies we cover in Biotech
- TNGX Tango Therapeutics Down 16.4%
- IOVA Iovance Down 35.4%
- VKTX Viking Therapeutics
- ARWR Arrowhead Down 15.3%
- XNCR Xencor Up 15.9%
- VERA Vera Down 1.2%
Show all 17
- NRIX Nurix Therapeutics Down 38.2%
- KRYS Krystal Down 11%
- AGIO Agios Down 9.9%
- CORT Corcept Therapeutics Down 20.1%
- TGTX TG Therapeutics Up 5.9%
- MDGL Madrigal Down 8.1%
- IMCR Immunocore Up 9.1%
- ORIC ORIC Pharmaceuticals Down 32%
- ALNY Alnylam
- GMAB Genmab Up 28.3%
- MRNA Moderna Down 17.6%
Questions about SELLAS
- Why did SELLAS stock rise on Nov 17, 2026?
- SELLAS said its Phase 3 REGAL trial of galinpepimut-S, a vaccine meant to keep acute myeloid leukemia from returning, met its main goal: patients lived a median 24.0 months, against 14.7 months on the doctors' choice of other treatment. The shares closed up about 156% at $19.15; these are company-reported topline results, the detailed analyses are still pending, and SELLAS has not yet applied for FDA approval. After the close, it filed to sell $150 million of new stock. Read the article →